NAD and fatigue: what has actually been tested?

A narrower answer than the advertisements

NAD is involved in cellular energy biology, but that fact alone does not demonstrate that a supplement relieves fatigue. The first question is what the investigators meant by fatigue. A questionnaire about drowsiness, a laboratory muscle test and ability to work through a normal day measure different things. A good claim identifies the symptom and the study population rather than treating energy as a single universal endpoint.

The older-adult NMN trial

Kim and colleagues randomized 108 older Japanese adults into morning or afternoon NMN and matching placebo groups for 12 weeks. They assessed sleep, questionnaire-based fatigue and physical performance. The abstract reports improvement in drowsiness in both afternoon groups, with the largest effect size in the afternoon NMN group. This detail matters: improvement from baseline is not automatically a treatment effect beyond placebo. The comparison between groups is the crucial test.

Why timing does not become a prescription

A study separating morning and afternoon administration can explore timing, but it does not establish the best schedule for an individual reader. Multiple groups and outcomes also create many opportunities for an interesting result. Look for a prespecified primary endpoint and consistent between-group differences, rather than selecting whichever questionnaire item looks most persuasive. A research protocol describes an experiment; it is not personal instructions.

Sleep research is related, but distinct

A separate 2024 study randomized 60 participants for 12 weeks and collected sleep outcomes as secondary endpoints. Its reported sleep signals invite further research, while its primary stepping test did not differ significantly between groups. Neither result should disappear from the summary. Better sleep scores in one trial do not establish treatment of persistent unexplained fatigue, and a walking measure cannot provide a missing fatigue diagnosis.

What a convincing fatigue study needs

A useful trial would enroll people with a clearly defined problem, measure symptoms with a suitable validated instrument, and report the absolute between-group change. It would also show whether that change was large enough to matter in daily life and whether it lasted. Retention, adverse events, concurrent treatments and blinding all affect credibility. A collection of enthusiastic customer comments cannot supply these missing controls.

Distinguish a scale from a story

When a trial uses a questionnaire, look for its name, scoring direction and comparison with placebo. A lower score might be favorable, but the practical meaning depends on which domain changed and by how much. An article should not convert a single drowsiness item into a sweeping statement about sustained mental and physical energy.

In a personal purchasing decision, subjective experience still matters, but it is difficult to attribute. Sleep, workload, expectations and other changes can occur at the same time as a new product. That makes a testimonial useful as an account of one person’s experience, while leaving the causal question open. Controlled evidence is needed to determine how much benefit the intervention itself adds.

A practical way to assess an offer

Ask whether the promised benefit is a measured human outcome or a biological story. Distinguish an oral precursor study from an injection service using NAD itself. Persistent or changing fatigue deserves clinical context rather than automatic attribution to a low NAD level. If considering a discretionary supplement purchase, set expectations around uncertainty and total recurring cost, and avoid treating an unvalidated test result as an explanation for the symptom.